ZA828048B - Novel anti-cancer drugs for the treatment of leukaemias t constituted by the chain a of ricin and a specific monoclonal antibody - Google Patents
Novel anti-cancer drugs for the treatment of leukaemias t constituted by the chain a of ricin and a specific monoclonal antibodyInfo
- Publication number
- ZA828048B ZA828048B ZA828048A ZA828048A ZA828048B ZA 828048 B ZA828048 B ZA 828048B ZA 828048 A ZA828048 A ZA 828048A ZA 828048 A ZA828048 A ZA 828048A ZA 828048 B ZA828048 B ZA 828048B
- Authority
- ZA
- South Africa
- Prior art keywords
- chain
- monoclonal antibody
- constituted
- leukaemias
- ricin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6819—Plant toxins
- A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
- A61K47/6827—Ricin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Botany (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR8121836A FR2516794B1 (fr) | 1981-11-20 | 1981-11-20 | Nouveaux medicaments anticancereux pour le traitement des leucemies t constitues de la chaine a de la ricine et d'un anticorps monoclonal specifique |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA828048B true ZA828048B (en) | 1983-08-31 |
Family
ID=9264235
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA828048A ZA828048B (en) | 1981-11-20 | 1982-11-03 | Novel anti-cancer drugs for the treatment of leukaemias t constituted by the chain a of ricin and a specific monoclonal antibody |
Country Status (10)
Country | Link |
---|---|
US (2) | US4643895A (ja) |
EP (1) | EP0080401B1 (ja) |
JP (1) | JPS58135821A (ja) |
AT (1) | ATE78699T1 (ja) |
AU (1) | AU561660B2 (ja) |
CA (1) | CA1209472A (ja) |
DE (1) | DE3280408T2 (ja) |
FR (1) | FR2516794B1 (ja) |
NZ (1) | NZ202563A (ja) |
ZA (1) | ZA828048B (ja) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2536997B1 (fr) * | 1982-03-11 | 1987-08-07 | Sanofi Sa | Medicaments cytotoxiques comportant au moins une immunotoxine et de la methylamine |
FR2523445A1 (fr) * | 1982-03-17 | 1983-09-23 | Sanofi Sa | Nouveaux conjugues associant, par liaison covalente, une enzyme et un anticorps, et associations medicamenteuses utilisant lesdits conjugues |
US4520226A (en) * | 1982-07-19 | 1985-05-28 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of graft versus host disease using a mixture of T-lymphocyte specific monoclonal antibody: ricin conjugates |
GB2137210B (en) * | 1983-03-30 | 1986-11-19 | Lilly Industries Ltd | Immunoglobulin conjugates |
US4664911A (en) * | 1983-06-21 | 1987-05-12 | Board Of Regents, University Of Texas System | Immunotoxin conjugates employing toxin B chain moieties |
FR2547731A1 (fr) * | 1983-06-27 | 1984-12-28 | Centre Nat Rech Scient | Immunotoxine antitumorale, preparations pharmaceutiques la contenant et son utilisation in vitro |
FR2550944B1 (fr) * | 1983-08-23 | 1985-12-06 | Sanofi Sa | Association pharmaceutique a base d'anticorps anticellules tumorales et de conjugues cytotoxiques, appropriee notamment pour le traitement des cancers |
ATE60233T1 (de) * | 1983-09-15 | 1991-02-15 | Univ Leland Stanford Junior | Allotransplantat mit verminderter immunogenitaet und verfahren und reagenz fuer seine herstellung. |
FR2564839B1 (fr) * | 1984-05-23 | 1986-11-14 | Sanofi Sa | Conjugues associant par liaison covalente un ionophore carboxylique monovalent et une macromolecule et leur utilisation comme agents potentialisateurs des immunotoxines |
CA1314245C (en) * | 1984-05-23 | 1993-03-09 | Franz Jansen | Process for the preparation of conjugates in which a monovalent carboxylic ionophore is associated by means of a covalent bond with a macromolecule, which are useful as immunotoxin potentiators |
FR2566271B1 (fr) * | 1984-06-20 | 1986-11-07 | Sanofi Sa | Nouveaux conjugues cytotoxiques utilisables en therapeutique et procede d'obtention |
US4670563A (en) * | 1984-06-20 | 1987-06-02 | Sanofi | Imidazolides as intermediates for the synthesis of cytotoxic conjugates |
FR2573656B1 (fr) * | 1984-11-29 | 1987-02-27 | Sanofi Sa | Medicament comportant en tant qu'association au moins une immunotoxine et au moins un polymere contenant du mannose |
FR2577135B1 (fr) * | 1985-02-13 | 1989-12-15 | Sanofi Sa | Immunotoxines a longue duree d'action comportant un constituant glycopeptidique inactivant les ribosomes modifie sur ses motifs polysaccharidiques |
US4698420A (en) * | 1985-02-25 | 1987-10-06 | Xoma Corporation | Antibody hybrid molecules and process for their preparation |
US4904481A (en) * | 1985-04-17 | 1990-02-27 | The Board Of Trustess Of Leland Stanford University | Method of conferring immuno-tolerance to a specific antigen |
ATE87318T1 (de) * | 1985-11-29 | 1993-04-15 | Consolidated Pharmaceuticals L | Ricin-antikoerper-konjugate. |
EP0252951A4 (en) * | 1986-01-06 | 1988-09-07 | Univ Melbourne | TECHNETIUM-ANTIBODY CONJUGATES. |
US4771128A (en) * | 1986-10-10 | 1988-09-13 | Cetus Corporation | Method of purifying toxin conjugates using hydrophobic interaction chromatography |
US4965392A (en) * | 1987-03-26 | 1990-10-23 | Neorx Corporation | Chelating compounds for metal-radionuclide labeled proteins |
US4981979A (en) * | 1987-09-10 | 1991-01-01 | Neorx Corporation | Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity |
US5171563A (en) * | 1988-09-30 | 1992-12-15 | Neorx Corporation | Cleavable linkers for the reduction of non-target organ retention of immunoconjugates |
EP0436664B1 (en) * | 1988-09-30 | 1994-11-09 | Neorx Corporation | Cleavable linkers for the reduction of non-target organ retention of immunoconjugates |
WO2008073160A2 (en) * | 2006-08-17 | 2008-06-19 | The Trustees Of Columbia University In The City Of New York | Methods for converting or inducing protective immunity |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2437213A1 (fr) * | 1978-09-28 | 1980-04-25 | Cm Ind | Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation |
JPS5616418A (en) * | 1979-07-20 | 1981-02-17 | Teijin Ltd | Antitumor protein complex and its preparation |
FR2466252A2 (fr) * | 1979-10-03 | 1981-04-10 | Clin Midy | Nouveaux produits ayant notamment des proprietes anticancereuses a base de chaine a de la ricine et d'une proteine |
EP0044167A3 (en) * | 1980-07-14 | 1982-04-21 | The Regents Of The University Of California | Antibody targeted cytotoxic agent |
FR2521010B1 (fr) * | 1982-02-09 | 1985-07-19 | Sanofi Sa | Medicaments comportant en tant qu'association au moins une immunotoxine et au moins un ionophore carboxylique monovalent |
FR2522968B1 (fr) * | 1982-03-10 | 1986-03-28 | Sanofi Sa | Medicament cytotoxique forme de l'association d'a u moins une immunotoxine et de la chloroquine |
FR2536997B1 (fr) * | 1982-03-11 | 1987-08-07 | Sanofi Sa | Medicaments cytotoxiques comportant au moins une immunotoxine et de la methylamine |
US4485093A (en) * | 1982-08-13 | 1984-11-27 | Runge Richard G | Immunotoxin conjugate which comprises arsanilic acid, useful for treating malignant tumors, particularly pancreatic cancer |
-
1981
- 1981-11-20 FR FR8121836A patent/FR2516794B1/fr not_active Expired
-
1982
- 1982-11-01 US US06/438,037 patent/US4643895A/en not_active Expired - Fee Related
- 1982-11-03 ZA ZA828048A patent/ZA828048B/xx unknown
- 1982-11-03 CA CA000414789A patent/CA1209472A/en not_active Expired
- 1982-11-10 AU AU90334/82A patent/AU561660B2/en not_active Ceased
- 1982-11-15 AT AT82402078T patent/ATE78699T1/de active
- 1982-11-15 DE DE8282402078T patent/DE3280408T2/de not_active Expired - Fee Related
- 1982-11-15 EP EP82402078A patent/EP0080401B1/fr not_active Expired - Lifetime
- 1982-11-19 NZ NZ202563A patent/NZ202563A/en unknown
- 1982-11-20 JP JP57202905A patent/JPS58135821A/ja active Pending
-
1988
- 1988-08-31 US US07/239,071 patent/US4919927A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
FR2516794B1 (fr) | 1985-10-25 |
US4919927A (en) | 1990-04-24 |
EP0080401B1 (fr) | 1992-07-29 |
DE3280408D1 (de) | 1992-09-03 |
CA1209472A (en) | 1986-08-12 |
EP0080401A1 (fr) | 1983-06-01 |
DE3280408T2 (de) | 1993-03-04 |
NZ202563A (en) | 1986-04-11 |
AU561660B2 (en) | 1987-05-14 |
US4643895A (en) | 1987-02-17 |
AU9033482A (en) | 1983-05-26 |
ATE78699T1 (de) | 1992-08-15 |
FR2516794A1 (fr) | 1983-05-27 |
JPS58135821A (ja) | 1983-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA828048B (en) | Novel anti-cancer drugs for the treatment of leukaemias t constituted by the chain a of ricin and a specific monoclonal antibody | |
IE820815L (en) | Anti-cancer drug. | |
NL7810176A (nl) | Gedoseerd farmaceutisch preparaat voor de behandeling van bacterieele infecties, alsmede verpakking voor een of meer doserings-eenheden van dit preparaat. | |
ATE46084T1 (de) | Immunotoxin-konjugate. | |
NL187516C (nl) | Werkwijze voor de bereiding van een proteine-concentraat uit melk dat immunoglobulinen bevat, en geneesmiddel tegen gastro-enteritis. | |
DE69331761D1 (de) | Arzneimittel, die den durch ampa rezeptoren vermittelten synaptischen respons erhöhen | |
OA05305A (fr) | Fermoir pour collier ou équivalent. | |
CN116528911A8 (zh) | 抗cd73抗体、抗体偶联药物及其用途 | |
EP0350690A3 (de) | Neutralisation der in vitro- und in vivo-toxischen Eigenschaften von TNF-alfa durch monoklonale Antikörper und die davon abgeleiteten Fragmente | |
DK0845998T3 (da) | Lægemidler til immunbehandling indeholdende antistoffer, der specifikt genkender MHCII-antigenet hos en patient, der skal behandles | |
ATE175215T1 (de) | Arzneimittel für die verlängerte immunsuppression und tumorzellelimination | |
NO922621L (no) | Farmasoeytiske preparater inneholdende antigen-antistoffkomplekser og anvendelser derav | |
AU2456888A (en) | Monoclonal antibodies specific for HIV and hybridomas for their production | |
ES450601A1 (es) | Un procedimiento para la preparacion de nuevos derivados de 4,5-diaril-2-(tiosustituido) michazol. | |
ATE104860T1 (de) | Aktiver wirkstoff und diesen enthaltendes arzneimittel zur verhinderung oder bekaempfung der abstossung von organtransplantaten. | |
FR2536997B1 (fr) | Medicaments cytotoxiques comportant au moins une immunotoxine et de la methylamine | |
ES2000615A6 (es) | Procedimiento para la preparacion del anticuerpo monoclonal designado como mak 436-15 del isotipo igg3" | |
FR2521010B1 (fr) | Medicaments comportant en tant qu'association au moins une immunotoxine et au moins un ionophore carboxylique monovalent | |
NL186860C (nl) | N,n'-bis-(3-picolyl)-4-methoxy-isoftalamidemonohydraat, werkwijze voor de bereiding daarvan en farmaceutische preparaten, die dit bevatten. | |
KR900005996A (ko) | 자기면역 질환의 치료 또는 예방을 위한 면역독소 | |
IT1233005B (it) | Anticorpo umano monoclonale, composizione terapeutica che lo contiene linea cellulare capace di produrre l'anticorpo, procedimento per la sua produzione | |
IT8722631A0 (it) | Derivati proteici del ferro altamente biodisponibile e tollerabili, loro preparazione e composizioni farmaceutiche che licontengono. | |
ATE110786T1 (de) | Monoklonaler antikörper gegen exotoxin a von pseudomonas aeruginosa. | |
FR2900M (fr) | Médicament a base de disulfure de bis (n-acéthylhydrazino-n'-carbonylméthyle) pour les traitements des inflammations. | |
IT8020016A0 (it) | Nuovi medicamenti per il trattamento dell'obesita'. |